Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.60 USD
Change Today -0.0005 / 0.00%
Volume 1.8K
LOXO On Other Exchanges
As of 10:02 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

loxo oncology inc (LOXO) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/5/14 - $16.45
52 Week Low
01/21/15 - $9.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LOXO ONCOLOGY INC (LOXO)

Related News

No related news articles were found.

loxo oncology inc (LOXO) Related Businessweek News

No Related Businessweek News Found

loxo oncology inc (LOXO) Details

Loxo Oncology, Inc. engages in the discovery, development, and commercialization of cancer therapies in the United States. Its lead product candidate includes LOXO-101, an oral and selective inhibitor of tropomyosin receptor kinase (TRK), which is in a Phase I dose escalation trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company’s preclinical programs include RET inhibitor that optimizes potency for RET fusion proteins, mutations, and clinically-identified resistance mutations; FGFR inhibitor that optimizes on potency against receptors comprising four isoforms with tyrosine kinase domains; and FLT3 inhibitor that optimizes on potency for the FLT3 internal tandem duplication mutations. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets. The company was founded in 2013 and is headquartered in Stamford, Connecticut.

11 Employees
Last Reported Date: 03/27/15
Founded in 2013

loxo oncology inc (LOXO) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $350.0K
Acting Chief Financial Officer
Total Annual Compensation: $127.4K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $189.7K
Compensation as of Fiscal Year 2014.

loxo oncology inc (LOXO) Key Developments

Loxo Oncology, Inc. Reports Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015 and 2017

Loxo Oncology, Inc. reported earnings results for the year ended December 31, 2014. For the year, the company reported net loss of $20,672,000 against $10,290,000 a year ago. Net loss attributable to common stockholders was $20,706,000 against $10,302,000 a year ago. Net loss per share of common stock, basic and diluted was $3.06 against $70.79 a year ago. The company expects a cash burn of $30.0 to $33.0 million in 2015. The company believes that, based upon its current operating plan, its existing capital resources will be sufficient to fund its anticipated operations into 2017.

Loxo Oncology, Inc. Announces Resignation of Josh Bilenker as Chief Executive Officer and Director

Josh Bilenker, M.D. resigned from the Board of Directors of Roka Bioscience, Inc., effective immediately, due to demands on his time and other professional commitments, including his role as Chief Executive Officer and director of Loxo Oncology, Inc. Dr. Bilenker indicated that his resignation was not the result of any disagreement with the Company on any matters relating to the Company's operations, policies or practices.

Loxo Oncology, Inc., 2015 Guidance/Update Call, Mar 02, 2015

Loxo Oncology, Inc., 2015 Guidance/Update Call, Mar 02, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LOXO:US $13.60 USD -0.0005

LOXO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LOXO.
View Industry Companies

Industry Analysis


Industry Average

Valuation LOXO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LOXO ONCOLOGY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at